Anavex Life Sciences (AVXL) Equity Average (2012 - 2025)
Anavex Life Sciences recorded quarterly Equity Average of $110.7 million in Q4 2025, up 19.19% quarter-over-quarter from $92.9 million in Q3 2025, and down 4.19% year-over-year from $115.6 million in Q4 2024.
Anavex Life Sciences' Equity Average history runs 13 years deep, the most recent figure standing at $110.7 million for Q4 2025.
- In Q4 2025, Equity Average fell 4.19% year-over-year to $110.7 million; the TTM figure through Dec 2025 stood at $110.7 million (down 4.19% YoY), while the FY2025 annual figure was $107.6 million, down 17.92% from the prior year.
- Equity Average came in at $110.7 million for Q4 2025 at Anavex Life Sciences, up from $92.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $154.0 million in Q3 2021 to a low of $61.1 million in Q1 2021.
- A 5-year average of $127.4 million and a median of $137.0 million in 2023 frame the typical range for Equity Average.
- Across the five-year window, Equity Average jumped 493.17% in 2021 and dropped 27.96% in 2025, its largest moves.
- Anavex Life Sciences' Equity Average stood at $148.6 million in 2021, then declined by 6.59% to $138.8 million in 2022, then decreased by 0.07% to $138.7 million in 2023, then dropped by 16.67% to $115.6 million in 2024, then dropped by 4.19% to $110.7 million in 2025.
- According to Business Quant data, Equity Average over the past three periods registered $110.7 million, $92.9 million, and $95.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 110.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110.74 Mn |
| Sep 30, 2025 | 92.91 Mn |
| Jun 30, 2025 | 95.36 Mn |
| Mar 31, 2025 | 105.34 Mn |
| Dec 31, 2024 | 115.59 Mn |
| Sep 30, 2024 | 125.02 Mn |
| Jun 30, 2024 | 132.37 Mn |
| Mar 31, 2024 | 135.27 Mn |
| Dec 31, 2023 | 138.71 Mn |
| Sep 30, 2023 | 144.30 Mn |
| Jun 30, 2023 | 145.96 Mn |
| Mar 31, 2023 | 140.14 Mn |
| Dec 31, 2022 | 138.81 Mn |
| Sep 30, 2022 | 146.61 Mn |
| Jun 30, 2022 | 151.47 Mn |
| Mar 31, 2022 | 149.29 Mn |
| Dec 31, 2021 | 148.59 Mn |
| Sep 30, 2021 | 153.98 Mn |
| Jun 30, 2021 | 116.48 Mn |
| Mar 31, 2021 | 61.06 Mn |
| Dec 31, 2020 | 36.77 Mn |
| Sep 30, 2020 | 25.96 Mn |
| Jun 30, 2020 | 24.74 Mn |
| Mar 31, 2020 | 25.38 Mn |
| Dec 31, 2019 | 23.12 Mn |
| Sep 30, 2019 | 20.74 Mn |
| Jun 30, 2019 | 19.19 Mn |
| Mar 31, 2019 | 18.32 Mn |
| Dec 31, 2018 | 20.89 Mn |
| Sep 30, 2018 | 22.95 Mn |
| Jun 30, 2018 | 23.03 Mn |
| Mar 31, 2018 | 24.01 Mn |
| Dec 31, 2017 | 25.71 Mn |
| Sep 30, 2017 | 24.67 Mn |
| Sep 30, 2015 | 9.69 Mn |
| Jun 30, 2015 | 5.64 Mn |
| Mar 31, 2015 | 2.59 Mn |
| Dec 31, 2014 | 332,876.00 |
| Sep 30, 2014 | 3.80 Mn |
| Jun 30, 2014 | 7.91 Mn |
| Mar 31, 2014 | 3.37 Mn |
| Dec 31, 2013 | -2.07 Mn |
| Sep 30, 2013 | -3.01 Mn |
| Jun 30, 2013 | -3.49 Mn |
| Mar 31, 2013 | -3.38 Mn |
| Dec 31, 2012 | -3.10 Mn |
| Sep 30, 2012 | -2.54 Mn |
| Jun 30, 2012 | -2.56 Mn |